Digbi Health has extended its genomic and gut microbiome platform to menopause care, combining hormone replacement therapy, GLP-1 prescribing, and metabolic and gastrointestinal management under a single clinical team. The rationale rests on member data showing 75% of women aged 40 to 60 already carry an obesity, cardiometabolic or gastrointestinal diagnosis. Separately released IBS outcomes from nearly 16,000 members show symptom improvement at 12 weeks, though the analysis lacks a control group and does not specify the measurement scale.
Key Points
- Menopause care now integrated with GLP-1, metabolic and gut programs
- Genetic and microbial markers used to estimate menopause timing, severity
- IBS results from 16,000 members lack control group, scale disclosure
Longevity Analysis
Midlife metabolic decline, shifting estrogen signaling, and gut dysfunction in women are typically managed as separate problems by separate clinicians, which obscures the degree to which they share upstream drivers. Reading genetic markers for menopause timing alongside microbial signatures governing estrogen metabolism is an attempt to interpret those overlapping signals before intervening, rather than treating each symptom in isolation. The efficacy claims warrant caution: the $3,012 per-member savings figure predates the hormone therapy offering, and symptom improvement without a comparison group cannot be cleanly separated from natural regression.
Original published by Longevity.Technology, by Kyle Umipig.